ClinicalTrials.gov
public full text
Public Domain
TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC
In this phase II trial with single arm, we aim to investigate the clinical efficacy and toxicity profile of local radiotherapy on all disease sites for EGFR-mutant oligo-metastatic NSCLC (no more than 3 metastatic lesions) who did not experience disease progression after at least 3 months of TKI therapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC#1454883
- Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Early Stereotactic Body Radiation Therapy to the Primary Tumor in Advanced Non-small Cell Lung Cancer#903125
- IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer#851528
- RT Plus EGFR-TKI for Wild-type NSCLC#900258
- Afatinib With CT and RT for EGFR-Mutant NSCLC#1087592
Record · ID 1453825
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive